Dan Rasmussen & D.A. Wallach on Biotech’s Surge, China, IPOs, US Valuations & Japan | #617

Episode Summary

Executive Summary: The episode centers on Dan Rasmussen’s year-long research into unprofitable biotech, arguing traditional equity factors fail there and must be redefined around biotech-specific measures like spend, specialist ownership, and peer momentum. The conversation then broadens to biotech’s rebound, China’s growing biotech ecosystem, Japan’s corporate reform story, and a macro debate about whether rising U.S. valuations reflect bubbles or structural shifts in profitability, deficits, and market participation.

Main Topics: Biotech factor investing framework (Priority: 5/5): Rasmussen explains why standard value, quality, and momentum signals break down in biotech and how he rebuilt them using market cap relative to spend, specialist ownership, and peer momentum derived from clinical-trial similarity. Biotech’s return dispersion and shorting opportunity (Priority: 5/5): The discussion highlights biotech’s extreme dispersion, high failure rate, and the potential for attractive short baskets when using the right multi-factor framework, while acknowledging fraud and face-ripping upside risks. China’s rising role in biotech (Priority: 5/5): Wallach and Rasmussen describe how Chinese biotech has moved from a peripheral player to a major source of molecules, faster and cheaper early-stage clinical work, and a growing destination for capital and talent. Valuation debate in U.S. equities (Priority: 4/5): The hosts contrast high CAPE readings with a reverse-DCF implied equity risk premium measure that looks more normal, debating whether U.S. valuation reflects overvaluation or a structural regime shift. Japan’s governance reform and capital returns (Priority: 4/5): Japan is presented as a compelling long-duration equity story driven by corporate governance changes, high balance sheets, rising dividends/buybacks, and potential private equity opportunity, despite cultural resistance to change. Market structure, deficits, and global asset prices (Priority: 4/5): A macro framework is advanced that links rising corporate profits, government deficits, lower corporate taxes, and expanding global participation in equities to long-run multiple expansion and high asset prices. Alpha, pod shops, and limits of stock picking (Priority: 3/5): DA Wallach argues that elite pod shops may define the practical upper bound of long-only stock-picking alpha, suggesting much of claimed outperformance is really beta or factor exposure.

Key Arguments: Biotech is unusually uncorrelated and internally dispersed, making it one of the most idiosyncratic sectors in public markets, but conventional factor models do not work there. For unprofitable biotech, value should be measured as market cap relative to spend, because cash is an asset rather than a liability and R&D spend proxies for scientific output. Specialist ownership is a practical quality signal: if the most informed biotech investors own a name, it is likely higher quality; if none do, it is a red flag. Peer momentum works better than direct momentum in biotech because scientific and therapeutic similarities cause stocks to move in clusters when comparable companies get positive news or M&A interest. Biotech shorting can work in basket form when names combine high valuation relative to spend, low specialist ownership, and weak peer momentum, but position sizing must account for extreme right-tail risks. China has become a serious biotech force due to years of state investment, lower-cost early clinical development, and increasing use by Big Pharma and Western companies. U.S. valuation optics are conflicting: CAPE looks historically expensive, but implied equity risk premium measures suggest equities may be closer to normal than critics assume. The post-2009 U.S. equity outperformance may reflect real structural factors such as tech innovation, rising profitability, tax changes, and deficit-driven demand for equities rather than pure multiple mania. Japan remains attractive because corporate balance sheets are bloated, payout ratios are low, governance reforms are improving distributions, and even modest normalization could drive years of returns. Private equity would theoretically work well in Japan because of under-distributed capital and low margins, but cultural resistance and deal scarcity make execution difficult. Elite pod shops may have effectively constrained long-only alpha generation to roughly 50-150 bps after costs, implying that many traditional active managers are overpromising. Long-run market leadership may be driven by shifting ownership participation, capital allocation, and global balance-sheet expansion as much as by conventional business-cycle narratives.

Data Points: Biotech share of U.S. companies: About 25% - Rasmussen says biotech is a large sector by count, though market caps are small. Unprofitable biotech loss rate: 70% - He notes that roughly 70% of unprofitable biotech public equities lose money. Biotech factor-research duration: A little over 1 year, almost 1.5 years - Time spent building the biotech-specific framework. Big Pharma acquisitions from China: 30% to 40% in 2025 - Share of Big Pharma acquisitions sourced from China, up from single digits five to six years earlier. Prior China acquisition share: Single digits - Historical benchmark before the recent rise in Chinese biotech sourcing. Specialist-holder threshold: More than $100 million of biotech and 50%+ biotech exposure - Definition used to identify specialist biotech holders. Typical specialist firm count: 15 to 20 firms - Approximate number of firms meeting the specialist definition at any point in time. Biotech drawdown vs. S&P: 60% to 100% underperformance episodes - Referenced as a severe relative drawdown that historically can precede strong recoveries. U.S. profit share of GDP, real basis: ~11 cents to 14 cents on the dollar - Profitability rose materially since COVID after inflation adjustment. U.S. profit share of GDP, nominal basis: ~11 cents to 18 cents on the dollar - The non-inflation-adjusted increase in corporate profits. Median Japanese company assets vs net income: About 7 years of net income in assets - Illustrates Japan’s excess balance-sheet capacity. Median U.S. company assets vs net income: About 1 year of net income in assets - Used as a comparison to Japan’s balance-sheet conservatism. Japanese small-cap value company assets: Up to 20 years of net income in assets - Extreme example of balance-sheet cash accumulation. Japan dividend/buyback payout ratio: About half of U.S. levels - Indicates room for payout growth under governance reform. U.S. market cap share of world equity: About 30% historically to about two-thirds today - Shows the long-run ascent of U.S. equities in global market capitalization. U.S. CAPE level: Around 41 - Mentioned as the current approximate Shiller CAPE at recording time. All-time low U.S. dividend yield: 1.1% - The dividend yield was near historical lows. U.S. productivity growth: Roughly 1.5% - Used in the argument that technology’s macro impact may be less dramatic than claimed. Internet-era productivity jump: From ~1.5% to ~3% - Used as a benchmark for how much a major innovation wave moved productivity. Alpha range at pod shops: 1.5% to 3% returns in long-short portfolios - DA Wallach’s estimate of what top pod shops can generate. Long-only alpha implication: 50 to 150 basis points - Wallach suggests long-only stock picking may be capped near this level after scaling down long-short results.

Pivotal Quotes: "everything we thought worked in regular world just worked the opposite in biotech" — Dan Rasmussen: Describing why biotech required a new factor model after standard equity signals failed. "the sector with the most dispersion internally" — Dan Rasmussen: Characterizing biotech as uniquely varied and difficult to analyze with normal tools. "Micro is what we do, macro is what we put up with" — Munger quote cited by Meb Faber: Used to frame the discussion about focusing on company-level work while accepting broader market forces.

Implications: Investors should treat biotech, Japan, and even U.S. valuations as regime-specific problems, not generic ones. In biotech, use specialist-aware signals; in Japan, watch governance reform; in the U.S., distinguish cyclical overvaluation from structural profit/deficit dynamics.